Key investor takeaways from NeurAxis Q1 FY2026 earnings call:
- Financial performance: Revenue was $1.6M in Q1 2026, up 80% year‑over‑year (Q1 2025: $0.896M). This was the company’s strongest quarterly revenue to date. Average selling price (ASP) rose 33% to $1,017 per device. Gross margin improved to 86.4% (up 200 basis points YoY). Operating loss narrowed to $1.7M and net loss to $1.8M. Cash on hand was approximately $7.1M at March 31, 2026 and ~ $8M after subsequent AT‑market raises. Free cash outflow in Q1 was $1.2M.
- KPIs and commercial traction: Covered lives ~101M. Internal prior authorization approval rate (for accounts they support) rose to 32% in Q1 from 12% in 2025. Number of ordering accounts was 66 (vs 56 in Q1 2025). Revenue per ordering account in Q1 was ~$24k (up 53% YoY). Unit deliveries rose 32% YoY.
- CPT code impact and payer strategy: The Category 1 CPT code (effective Jan 1, 2026) materially improved billing clarity and contributed to uptake, but the company emphasized that written medical policy coverage (payer policies) remains the single most important driver of scalable adoption. CPT code alone does not guarantee coverage; NeurAxis is prioritizing direct payer engagement, prior authorization support, and state Medicaid fee schedule implementation.
- Commercial focus and organization changes: The company is shifting from access-creation to execution, prioritizing depth in children’s hospitals (strongest evidence and policy momentum) and building out commercial leadership (new VP Sales, VP Marketing), targeted regional reps, medical science liaisons, digital marketing, and roles focused on clinical adoption/patient access. They are piloting integrated, high-intensity market initiatives and adding VA‑experienced personnel.
- VA and adult market: The VA channel is early but showing unexpected early orders; it is a strategic complementary channel that does not rely on commercial payer coverage in the same way. For broad adult commercial policy, NeurAxis has executed an agreement for a randomized controlled trial with Cleveland Clinic and Stanford to generate evidence for adult functional dyspepsia coverage.
- Expense and liquidity posture: Selling expenses will increase as the company hires to capture new coverage and demand; G&A is expected to hold roughly steady. A one‑time, mostly non‑cash stock‑compensation charge related to an option exchange is expected in Q2 (estimated > $4M). Management expects quarterly cash burn to continue declining toward approximately $1M or less for the remainder of the year. Using a ~75% variable margin assumption, management estimates cash‑flow breakeven on current SG&A/variable margin assumptions is roughly $15M of annual revenue (i.e., substantial runway improvement needed but achievable if adoption/coverage scales).
- Management view: The company believes Q1 validated the proof of concept: where payer coverage, physician champions, and dedicated clinic time exist, demand is strong. The strategy is to expand payer coverage while executing intensively in covered markets to convert access into sustained utilization. Management characterizes 2026 progress as the start of a multiyear growth cycle.
Sign In
Buy NRXS
